Vycor Medical, Inc. reported its financial results for the third quarter and the first nine months of 2025, showing a notable increase in revenue and a shift towards profitability compared to the previous fiscal period. For the three months ended September 30, 2025, the company generated revenue of $513,792, a 31% increase from $390,852 in the same period of 2024. The nine-month revenue also rose to $1,446,523, up 28% from $1,134,098 year-over-year. The gross profit for the quarter was $451,932, compared to $354,056 in the prior year, while the nine-month gross profit increased to $1,225,737 from $1,025,133.
The company’s operating income for the third quarter was $32,085, a significant turnaround from an operating loss of $35,135 in the same quarter of 2024. For the nine-month period, Vycor reported an operating income of $70,425, compared to a loss of $28,489 in the previous year. Despite these improvements, the net loss available to common stockholders for the third quarter was $157,249, down from a loss of $222,002 in the same period last year. The nine-month net loss was $334,110, compared to $424,833 in 2024.
In terms of operational developments, Vycor Medical's Vycor Medical segment, which focuses on neurosurgical devices, saw a revenue increase of 32% to $492,102 for the third quarter, primarily driven by growth in the U.S. market. The NovaVision segment, which provides rehabilitation therapies, also experienced a 20% revenue increase to $21,690. However, NovaVision's revenue for the nine months decreased slightly to $54,113 from $55,454, indicating a need for strategic reassessment in that division. The company continues to explore partnerships and acquisitions to enhance its market presence and product offerings.
The financial position of Vycor Medical showed a working capital deficiency of $4,152,481 as of September 30, 2025, an increase from $3,863,561 at the end of 2024. The company’s total assets decreased to $941,195 from $998,117, while total liabilities rose to $4,965,388 from $4,688,200. The company reported cash and cash equivalents of $64,230, down from $105,648 at the end of 2024. The management has expressed concerns regarding the company's ability to continue as a going concern, citing the need for additional financing to meet operational needs.
Looking ahead, Vycor Medical is focused on executing its growth strategy, which includes increasing market penetration in the U.S. and expanding internationally. The company is also considering additional equity or debt funding to support its operations and product development. However, management has acknowledged the uncertainty surrounding future financing and the potential impact of global economic conditions, including trade tariffs, on its operations. The company remains committed to reducing operating losses and enhancing its financial stability in the coming quarters.
About VYCOR MEDICAL INC
Vycor Medical, Inc. develops and markets medical devices for neurosurgery, including the ViewSite Brain Access System, and provides non-invasive vision rehabilitation therapies through NovaVision. Serving hospitals and patients worldwide, it offers minimally invasive surgical tools and digital health therapies. The company leverages regulatory approvals, innovative product development, and strategic partnerships to address neurological and vision impairment markets. Its business model focuses on device sales and therapy services in healthcare.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.